peg-interferon alfa-2a

Phase 3Small molecule

Bristol-Myers Squibb

peg-interferon alfa-2a is one of 213 small molecule programs targeting Thrombocytopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

212

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

Skin CancerActive, not recruiting

Chronic HepatitisActive, not recruiting

FibrosisActive, not recruiting

Plexiform NeurofibromaActive, not recruiting

Breast CancerActive, not recruiting

Hepatitis CActive, not recruiting

ThrombocytopeniaPhase 2

Active, not recruiting

Skin CancerPhase 1/Phase 2

Active, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

FibrosisPreclinical

Active, not recruiting

Plexiform NeurofibromaPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

peg-interferon alfa-2a

Bristol-Myers Squibb

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Adenocard

Astellas

Preclinical

1 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 9

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C2 trials

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01471574·549 enrolled

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01389323·448 enrolled

Chronic Hepatitis2 trials

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Unknown status·PPusan National University Hospital·Phase 3·NCT01769833·144 enrolled

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01544920·737 enrolled

HBV1 trial

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Completed·EEnyo Pharma·Phase 1·NCT03272009·73 enrolled

Treatment1 trial

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01125189·558 enrolled

Plexiform Neurofibroma1 trial

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00253474·36 enrolled

7 more indications

Fibrosis1 trial

Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03957629·186 enrolled

Breast Cancer1 trial

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00227656·2 enrolled

Phase II1 trial

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01573351·398 enrolled

Skin Cancer1 trial

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Unknown status·UUniversity of California, San Diego·Phase 1/2·NCT00423397·16 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02174172·158 enrolled

Thrombocytopenia1 trial

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Terminated·UUniversity of Southern California·Phase 2·NCT01153919·27 enrolled

Unspecified1 trial

Ph IIA Study (SOC +/- NS5B)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01193361·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for peg-interferon alfa-2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — peg-interferon alfa-2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for peg-interferon alfa-2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

peg-interferon alfa-2a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C2 trials

Chronic Hepatitis2 trials

HBV1 trial

Treatment1 trial

Plexiform Neurofibroma1 trial

Fibrosis1 trial

Breast Cancer1 trial

Phase II1 trial

Skin Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Thrombocytopenia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News